Valora Therapeutics is developing the AbLec (Antibody-Lectin chimera) platform to modulate glyco-immune checkpoints by precisely targeting specific sugar molecules on cells. The company aims to generate first-in-class and best-in-class therapeutics across oncology, autoimmune diseases, and other indications. AbLec technology is exclusively licensed from Stanford and builds on work from Dr. Carolyn Bertozzi and Dr. Jessica Stark, who are scientific founders and advisors to Valora. The $30 million seed financing will fund R&D to validate mechanisms of action and advance lead molecules into preclinical development. Valora has established R&D operations at the Avalon BioVentures Accelerator in San Diego, California, and plans to accelerate optimization of the AbLec platform toward the clinic. The company is led by CEO Miguel Garcia-Guzman, Ph.D., and emphasized that investor support will accelerate its development programs.

Total raised

$30M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2024